EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 958 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... December 9, 2025 Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... April 2, 2024 Co-Existing with COVID-19: Should I go back to work? Do I... June 19, 2020 Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... June 15, 2023 Load more HOT NEWS At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with... Colorectal Cancer Screening: Where Does the Shield Liquid Biopsy Fit In? FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma
